Alex Thompson
Stock Analyst at Stifel
(4.46)
# 949
Out of 5,180 analysts
41
Total ratings
65.71%
Success rate
16.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $70 → $92 | $48.90 | +88.14% | 3 | Mar 18, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $47 → $72 | $50.43 | +42.77% | 2 | Mar 13, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $56 → $85 | $56.73 | +49.83% | 3 | Mar 5, 2026 | |
| CLDX Celldex Therapeutics | Reiterates: Buy | $58 → $68 | $31.26 | +117.53% | 1 | Feb 26, 2026 | |
| ALMS Alumis | Initiates: Buy | $44 | $22.73 | +93.58% | 1 | Feb 25, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $5 | $1.88 | +165.96% | 1 | Feb 25, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $228.24 | +12.16% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $743.12 | +67.94% | 5 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $84.56 | -23.13% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $31.42 | -20.43% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $13.94 | +57.82% | 1 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $55 | $84.93 | -35.24% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $16.70 | +115.57% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $36.57 | +64.07% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $16.52 | +317.68% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $4.14 | -75.85% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $19.15 | +108.88% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $25.10 | +35.46% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.32 | +2,400.00% | 1 | Dec 14, 2022 |
Spyre Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $70 → $92
Current: $48.90
Upside: +88.14%
Oruka Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $47 → $72
Current: $50.43
Upside: +42.77%
AnaptysBio
Mar 5, 2026
Maintains: Buy
Price Target: $56 → $85
Current: $56.73
Upside: +49.83%
Celldex Therapeutics
Feb 26, 2026
Reiterates: Buy
Price Target: $58 → $68
Current: $31.26
Upside: +117.53%
Alumis
Feb 25, 2026
Initiates: Buy
Price Target: $44
Current: $22.73
Upside: +93.58%
Palisade Bio
Feb 25, 2026
Initiates: Buy
Price Target: $5
Current: $1.88
Upside: +165.96%
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $228.24
Upside: +12.16%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $743.12
Upside: +67.94%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $84.56
Upside: -23.13%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $31.42
Upside: -20.43%
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $13.94
Upside: +57.82%
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $84.93
Upside: -35.24%
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $16.70
Upside: +115.57%
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $36.57
Upside: +64.07%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $16.52
Upside: +317.68%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $4.14
Upside: -75.85%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $19.15
Upside: +108.88%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $25.10
Upside: +35.46%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.32
Upside: +2,400.00%